Delcath Systems, Inc. (DCTH)Healthcare | Medical Devices | Queensbury, United States | NasdaqCM
14.81 USD
+0.09
(0.611%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
After hours: 14.81 |
Hot Take ↕ | Oct. 10, 2026, 9:33 a.m. EDT
The investment case for Delcath Systems remains fundamentally broken despite recent operational headlines. While the company reports positive year-over-year revenue growth and has initiated a major clinical trial, the market has priced in a catastrophic failure of the business model, reflected in a trailing P/E of 1,536x and a cumulative loss of 98.7% over the last seven years. The balance sheet, while currently liquid due to cash reserves, masks a history of severe capital destruction where the stock has lost nearly all its value since 2018. The options market confirms this pessimism, with traders aggressively buying deep out-of-the-money puts for long-term protection while offering almost no call exposure. Until the company can demonstrate sustained profitability and a clear path to returning capital to shareholders beyond dilution, the risk-reward profile remains skewed heavily toward further downside. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.205060 |
| AutoARIMA | 0.205540 |
| MSTL | 0.207956 |
| AutoTheta | 0.208771 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 5.31 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.014 |
| Excess Kurtosis | -0.68 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.033 |
| Revenue per Share | 2.637 |
| Market Cap | 513,889,184 |
| Trailing P/E | 1481.00 |
| Forward P/E | 329.11 |
| Beta | 0.60 |
| Profit Margins | 0.56% |
| Website | https://www.delcath.com |
As of Oct. 10, 2026, 9:33 a.m. EDT: Speculators are positioning for a significant downside move, evidenced by massive open interest in out-of-the-money puts expiring in May 2027 (204 contracts vs zero calls). Conversely, call activity is negligible, with heavy open interest concentrated deep in-the-money strikes, suggesting a lack of bullish conviction despite some hedging activity near the money.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.19093847 |
| Address1 | 566 Queensbury Avenue |
| All Time High | 7,210.0 |
| All Time Low | 2.25 |
| Ask | 19.81 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Daily Volume10 Day | 313,790 |
| Average Daily Volume3 Month | 473,489 |
| Average Volume | 473,489 |
| Average Volume10Days | 313,790 |
| Beta | 0.597 |
| Bid | 11.25 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 3.498 |
| City | Queensbury |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 14.81 |
| Current Ratio | 9.83 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 14.965 |
| Day Low | 14.62 |
| Debt To Equity | 2.033 |
| Display Name | Delcath Systems |
| Dividend Date | 1,577,145,600 |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,019,400 |
| Earnings Call Timestamp Start | 1,786,019,400 |
| Earnings Growth | 0.0 |
| Earnings Quarterly Growth | -0.011 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,793,709,000 |
| Earnings Timestamp Start | 1,793,709,000 |
| Ebitda | -1,455,000 |
| Ebitda Margins | -0.01525 |
| Enterprise To Ebitda | -286.823 |
| Enterprise To Revenue | 4.374 |
| Enterprise Value | 417,327,264 |
| Eps Current Year | -0.135 |
| Eps Forward | 0.045 |
| Eps Trailing Twelve Months | 0.01 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 212 489 2102 |
| Fifty Day Average | 16.09 |
| Fifty Day Average Change | -1.2799997 |
| Fifty Day Average Change Percent | -0.0795525 |
| Fifty Two Week Change Percent | 19.093847 |
| Fifty Two Week High | 17.42 |
| Fifty Two Week High Change | -2.6099997 |
| Fifty Two Week High Change Percent | -0.14982776 |
| Fifty Two Week Low | 8.12 |
| Fifty Two Week Low Change | 6.6900005 |
| Fifty Two Week Low Change Percent | 0.8238917 |
| Fifty Two Week Range | 8.12 - 17.42 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,525,354,200,000 |
| Float Shares | 28,777,793 |
| Forward Eps | 0.045 |
| Forward P E | 329.1111 |
| Free Cashflow | 18,117,250 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 156 |
| Fullday Change | 0.09000015 |
| Fullday Change Percent | 0.6114141 |
| Fullday Price | 14.81 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.87052 |
| Gross Profits | 83,063,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.08085 |
| Held Percent Institutions | 0.51796 |
| Implied Shares Outstanding | 34,698,795 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Ir Website | http://www.delcath.com/investors/ |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,577,145,600 |
| Last Split Factor | 1:700 |
| Long Business Summary | Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York. |
| Long Name | Delcath Systems, Inc. |
| Market | us_market |
| Market Cap | 513,889,184 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_598622 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 532,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 553,792,768 |
| Number Of Analyst Opinions | 5 |
| Open | 14.7 |
| Operating Cashflow | 19,589,000 |
| Operating Margins | 0.08221 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.6 |
| Phone | 212 489 2100 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 14.81 |
| Post Market Time | 1,792,094,480 |
| Previous Close | 14.72 |
| Price Eps Current Year | -109.703705 |
| Price Hint | 2 |
| Price To Book | 4.233848 |
| Price To Sales Trailing12 Months | 5.385663 |
| Profit Margins | 0.00558 |
| Quick Ratio | 8.447 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.09000015 |
| Regular Market Change Percent | 0.6114141 |
| Regular Market Day High | 14.965 |
| Regular Market Day Low | 14.62 |
| Regular Market Day Range | 14.62 - 14.965 |
| Regular Market Open | 14.7 |
| Regular Market Previous Close | 14.72 |
| Regular Market Price | 14.81 |
| Regular Market Time | 1,792,094,401 |
| Regular Market Volume | 214,860 |
| Return On Assets | -0.0089300005 |
| Return On Equity | 0.00471 |
| Revenue Growth | 0.206 |
| Revenue Per Share | 2.637 |
| Sand P52 Week Change | 0.16440773 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 34,698,795 |
| Shares Percent Shares Out | 0.0561 |
| Shares Short | 1,947,041 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 2,242,281 |
| Short Name | Delcath Systems, Inc. |
| Short Percent Of Float | 0.061100002 |
| Short Ratio | 5.49 |
| Source Interval | 15 |
| State | NY |
| Symbol | DCTH |
| Target High Price | 32.0 |
| Target Low Price | 21.0 |
| Target Mean Price | 24.0 |
| Target Median Price | 22.0 |
| Total Cash | 95,902,000 |
| Total Cash Per Share | 2.764 |
| Total Debt | 2,463,000 |
| Total Revenue | 95,418,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.01 |
| Trailing P E | 1,481.0001 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 12.084075 |
| Two Hundred Day Average Change | 2.7259254 |
| Two Hundred Day Average Change Percent | 0.22557999 |
| Type Disp | Equity |
| Volume | 214,860 |
| Website | https://www.delcath.com |
| Zip | 12,804 |